OLBETAM

This brand name is authorized in Netherlands, New Zealand, Singapore, United Kingdom, South Africa

Active ingredients

The drug OLBETAM contains one active pharmaceutical ingredient (API):

1 Acipimox UNII K9AY9IR2SD - ACIPIMOX

Acipimox inhibits the release of fatty acids from adipose tissue and reduces the blood concentrations of very low density lipoproteins (VLDL or Pre-beta) and low density lipoproteins (LDL or beta) with a subsequent overall reduction in triglyceride and cholesterol levels. Read about Acipimox

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
OLBETAM Capsule	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C10AD06	Acipimox	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AD Nicotinic acid and derivatives
Discover more medicines within C10AD06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 146678, 36984
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 33030
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 4770
Country: SG	Health Sciences Authority	Identifier(s): 04543P
Country: ZA	Health Products Regulatory Authority	Identifier(s): W/7.5/365